In this issue:
10-year follow up data of nivolumab plus ipilimumab
Nivolumab monotherapy versus nivolumab plus ipilimumab
Efficacy of ctDNA in predicting tumour progression
Impact of DDIs on treatment outcomes
Precision of Melanoma Institute Australia SN tool
Does IFNα conditioning improve TIL outcomes
Risk of melanoma from UV exposure
Efficacy of dabrafenib for younger and older patients
7-year outcomes of ipilimumab plus nivolumab
Please login below to download this issue (PDF)